Large UK Biobank Study Links HRT Use to Lower Dementia Risk

What Happened

A new study from the University of East Anglia and the University of Exeter reports that hormone replacement therapy (HRT) use was associated with a lower risk of dementia in postmenopausal women.

The researchers analyzed UK Biobank health data from 183,450 postmenopausal women and published the findings in Alzheimer’s & Dementia.

• Data source: UK Biobank
• Follow-up: average 13.3 years
• Dementia cases identified during follow-up: almost 4,000

What The Evidence Shows In This Study

This was an observational study that assessed whether using HRT for at least one year was associated with later dementia risk, and whether the association varied by biological and genetic factors.

Across the cohort, HRT users were reported to be about 10% less likely to develop dementia and 16% less likely to develop Alzheimer’s disease than women who had never used HRT.

• Alzheimer’s disease risk: 16% lower in women who had used HRT vs never users
• Any dementia risk: about 10% lower in women who had used HRT vs never users

Which Groups Showed Stronger Associations

The study reported that the association between HRT use and lower dementia risk was not the same for all women, with stronger associations in several groups.

In women who had undergone surgical menopause, HRT use was associated with a 26% lower risk of developing any type of dementia compared with nonusers.

• Surgical menopause: 26% lower risk of any dementia with HRT vs no HRT
• Lower lifetime estrogen exposure (late periods or early menopause): 16% lower risk of any dementia with HRT
• APOE4 gene variant: stronger associations reported in carriers than noncarriers

Timing Findings Reported By The Authors

Age at HRT initiation was also linked to differences in outcomes in this analysis.

Women who began HRT between ages 46 and 56 experienced the greatest reduction in dementia risk in this dataset, which the authors note aligns with the “critical window” hypothesis.

• Greatest reduction reported when HRT started at ages 46 to 56
• The same level of benefit was not reported when HRT started outside this age range

Practical Context For Metabolic-Health Readers

The study’s senior author cited menopause-related effects on brain metabolism as one reason researchers are examining sex-specific factors in dementia risk, especially because women make up almost two-thirds of Alzheimer’s disease cases.

For readers tracking metabolic health alongside midlife hormone changes, this study adds to evidence that dementia risk may vary with menopause type, lifetime estrogen exposure, and APOE4 status. It does not establish that HRT causes risk reduction, but it helps define which groups may merit closer research and clinical discussion.

• If you are discussing midlife symptoms or risk factors with a clinician, this study points to menopause history (natural vs surgical), age at menopause, and family/genetic risk as factors researchers are analyzing
• The study reports different associations by subgroup, which may matter when weighing expected benefits and risks in shared decision-making

Limitations And Caveats From The Study Design

Because this was an observational analysis of health data, it can identify associations but cannot prove that HRT use directly reduces dementia risk.

The authors also report that the level of association differed by age at initiation and by subgroup, which means the average effect reported for the whole cohort may not apply to every individual.

• Observational design: association does not equal causation
• Findings depend on patterns of HRT use in the dataset, including initiation age and at least one year of use
• Reported benefits were not uniform across all women